250 related articles for article (PubMed ID: 24866126)
1. The in vivo therapeutic efficacy of the oncolytic adenovirus Delta24-RGD is mediated by tumor-specific immunity.
Kleijn A; Kloezeman J; Treffers-Westerlaken E; Fulci G; Leenstra S; Dirven C; Debets R; Lamfers M
PLoS One; 2014; 9(5):e97495. PubMed ID: 24866126
[TBL] [Abstract][Full Text] [Related]
2. Human bone marrow-derived mesenchymal stem cells for intravascular delivery of oncolytic adenovirus Delta24-RGD to human gliomas.
Yong RL; Shinojima N; Fueyo J; Gumin J; Vecil GG; Marini FC; Bogler O; Andreeff M; Lang FF
Cancer Res; 2009 Dec; 69(23):8932-40. PubMed ID: 19920199
[TBL] [Abstract][Full Text] [Related]
3. Locally-delivered T-cell-derived cellular vehicles efficiently track and deliver adenovirus delta24-RGD to infiltrating glioma.
Balvers RK; Belcaid Z; van den Hengel SK; Kloezeman J; de Vrij J; Wakimoto H; Hoeben RC; Debets R; Leenstra S; Dirven C; Lamfers ML
Viruses; 2014 Aug; 6(8):3080-96. PubMed ID: 25118638
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic concentrations of anti-epileptic drugs do not inhibit the activity of the oncolytic adenovirus Delta24-RGD in malignant glioma.
de Jonge J; Berghauser Pont LM; Idema S; Kloezeman JJ; Noske D; Dirven CM; Lamfers ML
J Gene Med; 2013; 15(3-4):134-41. PubMed ID: 23606319
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic virotherapy in glioblastoma patients induces a tumor macrophage phenotypic shift leading to an altered glioblastoma microenvironment.
van den Bossche WBL; Kleijn A; Teunissen CE; Voerman JSA; Teodosio C; Noske DP; van Dongen JJM; Dirven CMF; Lamfers MLM
Neuro Oncol; 2018 Oct; 20(11):1494-1504. PubMed ID: 29796615
[TBL] [Abstract][Full Text] [Related]
6. Low-dose oncolytic adenovirus therapy overcomes tumor-induced immune suppression and sensitizes intracranial gliomas to anti-PD-1 therapy.
Belcaid Z; Berrevoets C; Choi J; van Beelen E; Stavrakaki E; Pierson T; Kloezeman J; Routkevitch D; van der Kaaij M; van der Ploeg A; Mathios D; Sleijfer S; Dirven C; Lim M; Debets R; Lamfers MLM
Neurooncol Adv; 2020; 2(1):vdaa011. PubMed ID: 32642679
[TBL] [Abstract][Full Text] [Related]
7. The HDAC Inhibitors Scriptaid and LBH589 Combined with the Oncolytic Virus Delta24-RGD Exert Enhanced Anti-Tumor Efficacy in Patient-Derived Glioblastoma Cells.
Berghauser Pont LM; Kleijn A; Kloezeman JJ; van den Bossche W; Kaufmann JK; de Vrij J; Leenstra S; Dirven CM; Lamfers ML
PLoS One; 2015; 10(5):e0127058. PubMed ID: 25993039
[TBL] [Abstract][Full Text] [Related]
8. The Sequence of Delta24-RGD and TMZ Administration in Malignant Glioma Affects the Role of CD8
Kleijn A; van den Bossche W; Haefner ES; Belcaid Z; Burghoorn-Maas C; Kloezeman JJ; Pas SD; Leenstra S; Debets R; de Vrij J; Dirven CMF; Lamfers MLM
Mol Ther Oncolytics; 2017 Jun; 5():11-19. PubMed ID: 28480325
[TBL] [Abstract][Full Text] [Related]
9. An immune-competent, replication-permissive Syrian Hamster glioma model for evaluating Delta-24-RGD oncolytic adenovirus.
Phillips LM; Li S; Gumin J; Daou M; Ledbetter D; Yang J; Singh S; Parker Kerrigan BC; Hossain A; Yuan Y; Gomez-Manzano C; Fueyo J; Lang FF
Neuro Oncol; 2021 Nov; 23(11):1911-1921. PubMed ID: 34059921
[TBL] [Abstract][Full Text] [Related]
10. The oncolytic adenovirus Δ24-RGD in combination with cisplatin exerts a potent anti-osteosarcoma activity.
Martinez-Velez N; Xipell E; Jauregui P; Zalacain M; Marrodan L; Zandueta C; Vera B; Urquiza L; Sierrasesúmaga L; Julián MS; Toledo G; Fueyo J; Gomez-Manzano C; Torre W; Lecanda F; Patiño-García A; Alonso MM
J Bone Miner Res; 2014 Oct; 29(10):2287-96. PubMed ID: 24737304
[TBL] [Abstract][Full Text] [Related]
11. Delta-24-RGD oncolytic adenovirus elicits anti-glioma immunity in an immunocompetent mouse model.
Jiang H; Clise-Dwyer K; Ruisaard KE; Fan X; Tian W; Gumin J; Lamfers ML; Kleijn A; Lang FF; Yung WK; Vence LM; Gomez-Manzano C; Fueyo J
PLoS One; 2014; 9(5):e97407. PubMed ID: 24827739
[TBL] [Abstract][Full Text] [Related]
12. The therapeutic efficacy of the oncolytic virus Delta24-RGD in a murine glioma model depends primarily on antitumor immunity.
Kleijn A; Kloezeman J; Treffers-Westerlaken E; Fulci G; Leenstra S; Dirven C; Debets R; Lamfers M
Oncoimmunology; 2014 Oct; 3(9):e955697. PubMed ID: 25941622
[TBL] [Abstract][Full Text] [Related]
13. A comparative study of neural and mesenchymal stem cell-based carriers for oncolytic adenovirus in a model of malignant glioma.
Ahmed AU; Tyler MA; Thaci B; Alexiades NG; Han Y; Ulasov IV; Lesniak MS
Mol Pharm; 2011 Oct; 8(5):1559-72. PubMed ID: 21718006
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic HSV therapy increases trametinib access to brain tumors and sensitizes them in vivo.
Yoo JY; Swanner J; Otani Y; Nair M; Park F; Banasavadi-Siddegowda Y; Liu J; Jaime-Ramirez AC; Hong B; Geng F; Guo D; Bystry D; Phelphs M; Quadri H; Lee TJ; Kaur B
Neuro Oncol; 2019 Sep; 21(9):1131-1140. PubMed ID: 31063549
[TBL] [Abstract][Full Text] [Related]
15. Oncolytic adenovirus and gene therapy with EphA2-BiTE for the treatment of pediatric high-grade gliomas.
Arnone CM; Polito VA; Mastronuzzi A; Carai A; Diomedi FC; Antonucci L; Petrilli LL; Vinci M; Ferrari F; Salviato E; Scarsella M; De Stefanis C; Weber G; Quintarelli C; De Angelis B; Brenner MK; Gottschalk S; Hoyos V; Locatelli F; Caruana I; Del Bufalo F
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963009
[TBL] [Abstract][Full Text] [Related]
16. The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models.
Martínez-Vélez N; Garcia-Moure M; Marigil M; González-Huarriz M; Puigdelloses M; Gallego Pérez-Larraya J; Zalacaín M; Marrodán L; Varela-Guruceaga M; Laspidea V; Aristu JJ; Ramos LI; Tejada-Solís S; Díez-Valle R; Jones C; Mackay A; Martínez-Climent JA; García-Barchino MJ; Raabe E; Monje M; Becher OJ; Junier MP; El-Habr EA; Chneiweiss H; Aldave G; Jiang H; Fueyo J; Patiño-García A; Gomez-Manzano C; Alonso MM
Nat Commun; 2019 May; 10(1):2235. PubMed ID: 31138805
[TBL] [Abstract][Full Text] [Related]
17. Cellular factors promoting resistance to effective treatment of glioma with oncolytic myxoma virus.
Zemp FJ; McKenzie BA; Lun X; Reilly KM; McFadden G; Yong VW; Forsyth PA
Cancer Res; 2014 Dec; 74(24):7260-73. PubMed ID: 25336188
[TBL] [Abstract][Full Text] [Related]
18. Systemic administration of mesenchymal stem cells loaded with a novel oncolytic adenovirus carrying IL-24/endostatin enhances glioma therapy.
Zhang J; Chen H; Chen C; Liu H; He Y; Zhao J; Yang P; Mao Q; Xia H
Cancer Lett; 2021 Jul; 509():26-38. PubMed ID: 33819529
[TBL] [Abstract][Full Text] [Related]
19. Delta-24-RGD, an Oncolytic Adenovirus, Increases Survival and Promotes Proinflammatory Immune Landscape Remodeling in Models of AT/RT and CNS-PNET.
Garcia-Moure M; Gonzalez-Huarriz M; Labiano S; Guruceaga E; Bandres E; Zalacain M; Marrodan L; de Andrea C; Villalba M; Martinez-Velez N; Laspidea V; Puigdelloses M; Gallego Perez-Larraya J; Iñigo-Marco I; Stripecke R; Chan JA; Raabe EH; Kool M; Gomez-Manzano C; Fueyo J; Patiño-García A; Alonso MM
Clin Cancer Res; 2021 Mar; 27(6):1807-1820. PubMed ID: 33376098
[TBL] [Abstract][Full Text] [Related]
20. Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies.
van Putten EHP; Kleijn A; van Beusechem VW; Noske D; Lamers CHJ; de Goede AL; Idema S; Hoefnagel D; Kloezeman JJ; Fueyo J; Lang FF; Teunissen CE; Vernhout RM; Bakker C; Gerritsen W; Curiel DT; Vulto A; Lamfers MLM; Dirven CMF
Clin Cancer Res; 2022 Apr; 28(8):1572-1585. PubMed ID: 35176144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
